GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more
GlaxoSmithKline Pharmaceuticals Limited - Asset Resilience Ratio
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has an Asset Resilience Ratio of 35.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how GlaxoSmithKline Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down GlaxoSmithKline Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0% |
| Short-term Investments | ₹13.13 Billion | 35.83% |
| Total Liquid Assets | ₹13.13 Billion | 35.83% |
Asset Resilience Insights
- Very High Liquidity: GlaxoSmithKline Pharmaceuticals Limited maintains exceptional liquid asset reserves at 35.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GlaxoSmithKline Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare GlaxoSmithKline Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for GlaxoSmithKline Pharmaceuticals Limited (2014–2025)
The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 47.69% | ₹19.59 Billion | ₹41.08 Billion | -2.71pp |
| 2024-03-31 | 50.40% | ₹17.93 Billion | ₹35.57 Billion | +1.73pp |
| 2023-03-31 | 48.67% | ₹16.19 Billion | ₹33.27 Billion | -6.25pp |
| 2022-03-31 | 54.92% | ₹25.45 Billion | ₹46.33 Billion | +31.41pp |
| 2021-03-31 | 23.51% | ₹7.32 Billion | ₹31.13 Billion | -7.01pp |
| 2020-03-31 | 30.52% | ₹9.57 Billion | ₹31.36 Billion | +3.70pp |
| 2019-03-31 | 26.82% | ₹10.49 Billion | ₹39.11 Billion | +37.26pp |
| 2018-03-31 | -10.44% | ₹-4.12 Billion | ₹39.47 Billion | -35.98pp |
| 2017-03-31 | 25.54% | ₹7.67 Billion | ₹30.04 Billion | -15.56pp |
| 2016-03-31 | 41.10% | ₹12.52 Billion | ₹30.46 Billion | -15.96pp |
| 2015-03-31 | 57.06% | ₹18.40 Billion | ₹32.24 Billion | +56.74pp |
| 2014-03-31 | 0.32% | ₹100.03 Million | ₹31.30 Billion | -- |